期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗恶性淋巴瘤临床研究进展 被引量：2

下载PDF
导出
摘要 蛋白酶体是真核细胞内蛋白降解必需的重要组成成分,通过泛素-蛋白酶体通路发挥重要作用[1].蛋白酶体是一个重要的作用靶点,可以影响多种在肿瘤的发生及演变过程中发挥重要作用的调节蛋白.蛋白酶体抑制剂已成为肿瘤治疗中令人关注的焦点.硼替佐米是哺乳动物细胞中26S蛋白酶体糜蛋白酶样活性的可逆抑制剂,其对多种肿瘤都有很好的治疗效果,如淋巴瘤、白血病、乳腺癌等,已经是抗癌领域的先锋药[2].本文就其在恶性淋巴瘤治疗方面的临床研究进展进行综述.
作者 牛业来 宋伟
机构地区 山东省滨州市中心医院肿瘤科 山东大学附属省立医院肿瘤治疗中心
出处 《中国医药》 2015年第4期601-603,共3页 China Medicine
关键词 淋巴瘤 硼替佐米 泛素-蛋白酶体通路 淋巴瘤 非霍奇金
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Adams J. The proteasome : a suitable antineoplastic target [ J ]. Nat Rev Cancer, 2004,4(5) :349-360.
  • 2杜登学,王姗姗,宫风华,周磊,张志鹏.蛋白酶抑制剂类抗癌药物的研究进展[J].化学与生物工程,2011,28(6):7-11. 被引量：2
  • 3黄耿文,丁翔,雷鹏.硼替佐米对大鼠肾移植AMR的保护作用及机制研究[J].实用药物与临床,2014,17(12):1560-1563. 被引量：3
  • 4徐秀月,王凌云,姜秀春,彭大影,王德军.硼替佐米治疗多发性骨髓瘤疗效及影响因素分析[J].实用药物与临床,2012,15(9):561-563. 被引量：9
  • 5Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy[J]. Cancer Cell Int, 2005,5(1) :18.
  • 6Paramore A, Frantz S. Bortezomib [ J ]. Nat Rev Drug Discov, 2003,2(8) :611-612.
  • 7Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the protea- some inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer [ J 1. J Clin On- col, 2004,22(11) :2108-2121.
  • 8Goy A, Younes A, McLaughlin P, et al. Phase Ⅱ study of protea- some inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin's lymphoma[ J]. J Clin Oncol, 2005,23 (4):667-675.
  • 9Fisher RI, Bernstein SH, Kahl BS, et al. Muhicenter phase Ⅱstudy of bortezomib in patients with relapsed or refractory mantle cell lymphoma [ J ]. J Clin Oncol, 2006,24 (30) :4867 4874.
  • 10Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma : updated time-to-event analyses of the muhicenter phase 2 PINNACLE study [ J]. Ann Oncol, 2009,20(3) :520-525.

二级参考文献43

  • 1Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time- to-event analyses of the multicenter phase 2 PINNACLE study [J]. Ann Oncol,2009,20(3) :520-525.
  • 2Ghosh N, Ye X, Ferquson A, et al. Bortezomib and thalido- mide. a steroid free regimen in newly diagnosed patients with multiple myeloma [ J ]. Br J Haematol, 2011,152 ( 17 ) : 593-598.
  • 3Goy A,Bernstein SH,Kahl BS,et al.Bortezomib in patients with relapsed or refractory mantle cell lymphoma:updated time-to-event analyses of the multicenter phase 2 PINNACLE study[J].J Ann Oncol,2009,20:520-525.
  • 4Le Blanc R,Catley LP,Hideshima T,et al.Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survivali n a murine model[J].Cancer Res,2002,62(17):4996-5000.
  • 5Goy A,Younes A,McLaughlin P,et al.Phase I study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma[J].J Clin Oncol,2005,23(4):667-675.
  • 6Sors A,Jean-Louis F,Pellet C,et al.Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis[J].Blood,2006,107(6):2354-2363.
  • 7Gerecitano J,Portlock C,Hamlin P,et al.Phase I trial of weekly and twice-weekly bortezomib with rituximab,cyclophosphamide,and prednisone in relapsed or refractory non-Hodgkin lymphoma[J].Clin Cancer Res,2011,17(8):2493-2501.
  • 8Belch A, Kouroukis CT, Crump M, et al. A phase II study of borte- zomib in mantle cell lymphoma : the National Cancer Institute of Cana- da Clinical Trials Group trial IND. 150 [ J ]. Annals of Oncology, 2007, 18(1): 116-121.
  • 9Strauss SJ, Maharaj L. Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activi- ty [J]. J ClinicalOncology,2006, 24(13): 2105 -2112.
  • 10Lai GM, Chen YN, Mickley LA, et al. P - glycoprotein expression and schedule dependence of adriamycin cytotnxicity in human colon carcinoma cell lines [ J]. International Journal of Cancer Journal In- ternational Du Cancer, 1991, 49(5) : 696 -703.

共引文献20

同被引文献25

引证文献2

二级引证文献22

中国医药
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部